Domestic listing status and purchase channels of Dali Leisen

Daridorexant is a new orexin receptor antagonist mainly used to treat adult insomnia patients with difficulty falling asleep and/or sleep maintenance disorders. It blocks the arousal signaling pathway in the brain, that is, inhibits the activity of orexin (Orexin) receptors, thereby helping patients fall asleep more easily and stay asleep throughout the night. This drug was developed by the Swiss pharmaceutical company Idorsia. As a type of non-benzodiazepine sedative with a unique mechanism of action, it has been widely used in Europe and the United States in recent years and has received great attention from the clinical community.

On June 17, 2025, the original drug of DaliRasen was officially approved for marketing by the China National Medical Products Administration (NMPA), marking that this internationally advanced treatment method has entered the domestic clinical application stage. However, due to its short time on the market, the current price, medical insurance reimbursement status and hospital penetration rate in mainland China have not yet been announced, and the circulation channels available to the public are still relatively limited. Before it is officially entered into the medical insurance directory, if patients need it urgently, they may consider purchasing it through regular overseas pharmacies or cross-border medical service platforms.

At this stage, the original drug of Dali Rasen that is common in foreign markets is mainly packaged in European version. The common specification is 50 mg × 30 tablets per box. The price is about RMB 2,000, but the price may fluctuate due to factors such as exchange rates and logistics channels. At present, no generic drugs have been approved for marketing in China, so the main purchasing options are still original drugs. Before taking the medication, the patient will have a doctor evaluate the type and severity of the sleep disorder to ensure the medication is safe and effective.

With the acceleration of domestic drug review and approval, the accessibility of DaliRasen in hospital pharmacies is expected to be further improved in the future, and it may also be included in medical insurance negotiations to provide a more affordable and accessible treatment option for the majority of insomnia patients.

Reference materials:https://www.quviviq.com/